Steroid controversy?
Corticosteroids in the Treatment of Severe Sepsis and Septic Shock in Adults - A Systematic Review
Context:The benefit of corticosteroids in severe sepsis and septic shock remains controversial.
Objective: We examined the benefits and risks of corticosteroid treatment in severe sepsis and septic shock and the influence of dose and duration.
Design: We searched the CENTRAL, MEDLINE, EMBASE, and LILACS (through March 2009) databases as well as reference lists of articles and proceedings of major meetings, and we contacted trial authors. All reviewers agreed on trial eligibility. One reviewer extracted data, which were checked by the other reviewers and by the trials' authors whenever possible. Some unpublished data were obtained from the trials' authors. The primary outcome for this review was 28-day mortality.
Results: We identified 17 randomized trials (n = 2138) and 3 quasi-randomized trials (n = 246) that had acceptable methodological quality to pool in a meta-analysis.
- Twenty-eight-day mortality for treated vs control patients was 35.3% vs 38.5% in randomized trials and 23.1% vs 19.2% in quasi-randomized trials
- In 12 trials investigating prolonged low-dose corticosteroid treatment, 28-day mortality for treated vs control patients was 37.5% vs 44%
- This treatment increased 28-day shock reversal 66.9% vs 58.6%; and reduced intensive care unit length of stay by 4.49 days without increasing the risk of gastroduodenal bleeding [8.1% vs 7.3%, superinfection [18.4% vs 17.9%], or neuromuscular weakness [1% 1.7%].
- Corticosteroids increased the risk of hyperglycemia [51.6% vs 46%] and hypernatremia (31.4% vs 19.2%]
Corticosteroids in the Treatment of Severe Sepsis and Septic Shock in Adults - A Systematic Review - Djillali Annane, MD; Eric Bellissant, MD; Pierre-Edouard Bollaert, MD; Josef Briegel, MD; Marco Confalonieri, MD; Raffaele De Gaudio, MD; Didier Keh, MD; Yizhak Kupfer, MD; Michael Oppert, MD; G. Umberto Meduri, MD - JAMA. 2009;301(22):2362-2375.